glp 1 agonist vs sglt2 inhibitor Disparities in or Glucagon-Like Peptide Receptor Initiation Among Medicare-Insured Adults With CKD in the United States Use of GLP-1 Receptor Agonists
Description
Although preclinical studies suggest that GLP-1RAs may attenuate Alzheimers disease (AD) progression [44, 45], phase III semaglutide trials (NCT04777396, NCT04777409) did not demonstrate clinical benefit
10.1210/en.2014-1978 74 PerkovicV.TuttleK
However, this technique is impractical in the clinical setting and it is mostly used for research purposes
Looking at the global market, GLP-1RA has steadily increased its share in the market of hypoglycemic drugs
GLP-1R mediates idebenone-reduced blood glucose in mice
doi: 10.15620/cdc:106273
